Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Research

Olfactory mucosa mesenchymal stem cells alleviate pulmonary fibrosis via the immunomodulation and reduction of inflammation

Authors: Ran Duan, Chun-Gu Hong, Xin Wang, Ming Lu, Hui Xie, Zheng-Zhao Liu

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Pulmonary fibrosis (PF) is a progressive fibrosing interstitial pneumonia that leads to respiratory failure and other complications, which is ultimately fatal. Mesenchymal stem cells (MSCs) transplant is a promising strategy to solve this problem, while the procurement of MSCs from the patient for autotransplant remains a challenge.

Methods

Here, we presented olfactory mucosa mesenchymal stem cells (OM-MSCs) from mouse turbinate and determined the preventing efficacy of allotransplant for PF. We demonstrated the antiinflammation and immunomodulatory effects of OM-MSCs. Flow cytometric analysis was used to verify the effect of OM-MSCs on monocyte-derived macrophage populations in the lung.

Results

Administration of OM-MSCs reduces inflammation, attenuates the matrix metallopeptidase 13 (MMP13) expression level and restores the bleomycin (BLM)-induced pulmonary fibrosis by assessing the architecture of lung, collagen type I; (COL1A1), actin alpha 2, smooth muscle, aorta (ACTA2/α-SMA) and hydroxyproline. This therapeutic effect of OM-MSCs was related to the increase in the ratio of nonclassical monocytes to proinflammatory monocytes in the lung.

Conclusions

This study suggests that transplant of OM-MSCs represents an effective and safe treatment for PF.
Appendix
Available only for authorised users
Literature
1.
Richeldi L, Collard HR, Jones MG. Idiopathic Pulmonary Fibrosis. Lancet (London England). 2017;389(10082):1941–52.CrossRefPubMed
2.
Liu Y-M, Nepali K, Liou J-P. Idiopathic Pulmonary Fibrosis: current status, recent progress, and emerging targets. J Med Chem. 2017;60(2):527–53.CrossRefPubMed
3.
Plantier L, Cazes A, Dinh-Xuan A-T, Bancal C, Marchand-Adam S, Crestani B. Physiology of the lung in Idiopathic Pulmonary Fibrosis. Eur Respir Rev. 2018;27(147).
4.
Herberts MB, Teague TT, Thao V, Sangaralingham LR, Henk HJ, Hovde KT, et al. Idiopathic Pulmonary Fibrosis in the United States: time to diagnosis and treatment. BMC Pulm Med. 2023;23(1):281.CrossRefPubMedPubMedCentral
5.
Lee JH, Park HJ, Kim S, Kim YJ, Kim HC. Epidemiology and comorbidities in Idiopathic Pulmonary Fibrosis: a nationwide cohort study. BMC Pulm Med. 2023;23(1):54.CrossRefPubMedPubMedCentral
6.
Baratella E, Ruaro B, Giudici F, Wade B, Santagiuliana M, Salton F et al. Evaluation of correlations between genetic variants and high-resolution computed tomography patterns in Idiopathic Pulmonary Fibrosis. Diagnostics (Basel). 2021;11(5).
7.
Ruaro B, Salton F, Braga L, Wade B, Confalonieri P, Volpe MC et al. The history and mystery of alveolar epithelial type II cells: focus on their physiologic and pathologic role in lung. Int J Mol Sci. 2021;22(5).
8.
Confalonieri P, Volpe MC, Jacob J, Maiocchi S, Salton F, Ruaro B et al. Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF). Cells. 2022;11(13).
9.
Savin IA, Zenkova MA, Sen’kova AV. Pulmonary fibrosis as a result of Acute Lung inflammation: Molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches. Int J Mol Sci. 2022;23(23).
10.
Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic Pulmonary Fibrosis. Nat Reviews Disease Primers. 2017;3:17074.CrossRefPubMed
11.
Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of Idiopathic Pulmonary Fibrosis: what is next? Eur Respir Rev. 2019;28(153).
12.
13.
Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181–94.CrossRefPubMed
14.
Mansouri N, Willis GR, Fernandez-Gonzalez A, Reis M, Nassiri S, Mitsialis SA et al. Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes. JCI Insight. 2019;4(21).
15.
Joshi N, Watanabe S, Verma R, Jablonski RP, Chen C-I, Cheresh P et al. A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages. Eur Respir J. 2020;55(1).
16.
Huang Y, Tan F, Zhuo Y, Liu J, He J, Duan D et al. Hypoxia-preconditioned olfactory mucosa mesenchymal stem cells abolish cerebral ischemia/reperfusion-induced pyroptosis and apoptotic death of microglial cells by activating HIF-1α. Aging (Albany NY). 2020;12.
17.
18.
Lindsay SL, Johnstone SA, McGrath MA, Mallinson D, Barnett SC. Comparative miRNA-Based fingerprinting reveals Biological differences in human olfactory mucosa- and bone-marrow-derived mesenchymal stromal cells. Stem Cell Reports. 2016;6(5):729–42.CrossRefPubMedPubMedCentral
19.
Lindsay SL, Toft A, Griffin J, Emraja MM, Barnett A, Riddell SC. Human olfactory mesenchymal stromal cell transplants promote remyelination and earlier improvement in gait co-ordination after spinal cord injury. Glia. 2017;65(4):639–56.CrossRefPubMedPubMedCentral
20.
Hong CG, Chen ML, Duan R, Wang X, Pang ZL, Ge LT et al. Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer’s Disease. Mol Neurobiol. 2022.
21.
Hübner R-H, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44(4).
22.
Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41(4):467–70.CrossRefPubMedPubMedCentral
23.
Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, et al. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with Idiopathic Pulmonary Fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulm Med. 2020;20(1):64.CrossRefPubMedPubMedCentral
24.
Nkyimbeng T, Ruppert C, Shiomi T, Dahal B, Lang G, Seeger W, et al. Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in Idiopathic Pulmonary Fibrosis. PLoS ONE. 2013;8(9):e73279.CrossRefPubMedPubMedCentral
25.
King TE, Pardo A, Selman M. Idiopathic Pulmonary Fibrosis. Lancet (London England). 2011;378(9807):1949–61.CrossRefPubMed
26.
27.
Rudd RM, Prescott RJ, Chalmers JC, Johnston ID, Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic S. British thoracic society study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax. 2007;62(1):62–6.CrossRefPubMed
28.
King TE Jr., Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr., et al. Idiopathic Pulmonary Fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164(6):1025–32.CrossRefPubMed
29.
Toonkel RL, Hare JM, Matthay MA, Glassberg MK. Mesenchymal stem cells and Idiopathic Pulmonary Fibrosis. Potential for clinical testing. Am J Respir Crit Care Med. 2013;188(2):133–40.CrossRefPubMed
30.
Amable PR, Teixeira MVT, Carias RBV, Granjeiro JM, Borojevic R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. Stem Cell Res Ther. 2014;5(2):53.CrossRefPubMedPubMedCentral
31.
Simones AA, Beisang DJ, Panoskaltsis-Mortari A, Roberts KD. Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review. Pediatr Res. 2018;83(1–2):308–17.CrossRefPubMed
32.
Huard JM, Youngentob SL, Goldstein BJ, Luskin MB, Schwob JE. Adult olfactory epithelium contains multipotent progenitors that give rise to neurons and non-neural cells. J Comp Neurol. 1998;400(4):469–86.CrossRefPubMed
33.
Ge L, Jiang M, Duan D, Wang Z, Qi L, Teng X, et al. Secretome of olfactory mucosa mesenchymal stem cell, a multiple potential stem cell. Stem Cells Int. 2016;2016:1243659.CrossRefPubMedPubMedCentral
34.
Delorme B, Nivet E, Gaillard J, Häupl T, Ringe J, Devèze A, et al. The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev. 2010;19(6):853–66.CrossRefPubMed
35.
Rui K, Zhang Z, Tian J, Lin X, Wang X, Ma J, et al. Olfactory ecto-mesenchymal stem cells possess immunoregulatory function and suppress autoimmune arthritis. Cell Mol Immunol. 2016;13(3):401–8.CrossRefPubMed
36.
Abreu SC, Antunes MA, Pelosi P, Morales MM, Rocco PRM. Mechanisms of cellular therapy in Respiratory Diseases. Intensive Care Med. 2011;37(9):1421–31.CrossRefPubMed
37.
Moradi M, Rezaee MA, Mohammadi M, Rezaie MJ, Jalili A, Rahmani MR. Attenuating effect of long-term culture of umbilical cord vein mesenchymal stromal cells on pulmonary fibrosis in C57BL/6 mice. Iran J Allergy Asthma Immunol. 2017;16(6):501–10.PubMed
38.
Chen S, Cui G, Peng C, Lavin MF, Sun X, Zhang E, et al. Transplantation of adipose-derived mesenchymal stem cells attenuates pulmonary fibrosis of silicosis via anti-inflammatory and anti-apoptosis effects in rats. Stem Cell Res Ther. 2018;9(1):110.CrossRefPubMedPubMedCentral
39.
Choi SM, Mo Y, Bang JY, Ko YG, Ahn YH, Kim HY, et al. Classical monocyte-derived macrophages as therapeutic targets of umbilical cord mesenchymal stem cells: comparison of intratracheal and intravenous administration in a mouse model of pulmonary fibrosis. Respir Res. 2023;24(1):68.CrossRefPubMedPubMedCentral
40.
Chang YS, Oh W, Choi SJ, Sung DK, Kim SY, Choi EY, et al. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transpl. 2009;18(8):869–86.CrossRef
41.
Tanni SE, Fabro AT, de Albuquerque A, Ferreira EVM, Verrastro CGY, Sawamura MVY, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med. 2021;15(6):791–803.CrossRefPubMed
42.
43.
Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus Infections: applicability to COVID-19. Eur Respir J. 2020;55(6).
Metadata
Title
Olfactory mucosa mesenchymal stem cells alleviate pulmonary fibrosis via the immunomodulation and reduction of inflammation
Authors
Ran Duan
Chun-Gu Hong
Xin Wang
Ming Lu
Hui Xie
Zheng-Zhao Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-023-02834-5

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue

Research

Factors associated with non-fatal heart failure and atrial fibrillation or flutter within the first 30 days post COPD exacerbation: a nested case-control study

Research

The total-breath method yields higher values of DLCO and TLC than the conventional method

Research

Incidence of noninvasive ventilation failure and mortality in patients with acute respiratory distress syndrome: a systematic review and proportion meta-analysis

Case Report

Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report

Research

Outcomes of coronary artery bypass grafting (CABG) in patients with OSA-COPD overlap syndrome versus COPD alone: an analysis of US Nationwide Inpatient Sample

Research

Longitudinal analysis of quality of life in primary lung cancer patients with chlamydia pneumoniae infection: a time-to-deterioration model
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits